Navigation Links
US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
Date:2/28/2008

16.7 million in the fourth quarter of 2006 due primarily to higher personnel costs, which reflect annual merit increases and personnel investments made to support our expanded regional infrastructure. Compared to the third quarter of 2007, corporate costs were essentially flat.

During calendar 2007, corporate costs were $83.6 million, an increase of $8.6 million from 2006. The increase is due to higher 2007 personnel costs (as discussed previously), as well as increased marketing costs to support our marketing efforts and expenses associated with an upgrade of the company's financial information system.

Impairment and Restructuring Charges

We continue to align our agreements with the service needs and maturity of our affiliated practices. During December 2007, eleven physicians from a practice previously affiliated under a comprehensive service agreement entered into a binding agreement to convert to an oncology pharmaceutical services agreement effective December 31, 2007. The company recognized an impairment charge of $6.5 million related to this practice, which relates primarily to a $4.7 million write-off of our service agreement intangible asset that was terminated in connection with the conversion.

Net Income (Loss)

Net loss for the fourth quarter of 2007 was $14.8 million, a decrease of $18.1 million from net income of $3.3 million the fourth quarter of 2006 and a decrease of $10.6 million from the third quarter of 2007. When compared to the fourth quarter of 2006 and the third quarter of 2007, the decrease resulted from the impairment charges described previously, increased interest expense reflecting additional borrowings and a loss on an interest rate swap.

For calendar year 2007, the net loss was $35.0 million, a decrease of $61.2 million compared to fiscal year 2006 net income of $26.2 million. Excluding impairment and restructuring charges, income from operations decreased $35.9 million due primarily to the impa
'/>"/>

SOURCE US Oncology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
(Date:6/26/2015)... ... June 26, 2015 , ... Claremont BioSolutions, LLC, a ... been integrated into a sample prep module intended to enable real-time quantitative gene ... the NASA’s WetLab-2 Project. , On June 28, 2015, SpaceX CRS-7 will launch ...
(Date:6/26/2015)... ... 26, 2015 , ... ReliantHeart, Inc. , an innovative supplier of advanced ... of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, there has been no ... in an LVAD is referred to as de novo thrombus. De novo thrombus can ...
Breaking Biology Technology:Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3
... FOLD ) today announced that John Crowley, President and ... Merrill Lynch,Global Pharmaceutical, Biotech & Medtech 2007 Conference in ... BDT (11:00 am EDT) at the,Merrill Lynch Financial Centre. ... will be available to all,interested parties through the Investors ...
... a,biotechnology company translating the complexity of human biology ... president and,CEO, Dr. Keith O. Elliston, has been ... in Arlington, Va., September 17-18. Dr. Elliston ... Development and Commercial Value Added in Care Delivery ...
... ... and Reusable Bottles, MONROVIA, Calif., Sept. 12 Bottled or ... of consumers who fear the impact of,bottled water on the environment, ... assembled a family of products on its website, http://www.discovertesting.com, in ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit 2Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled 2
(Date:6/23/2015)... June 22, 2015 ... addition of the "Body-Worn Temperature Sensors Market ... and Forecast 2014 - 2020" report to ... analysis of the global body-worn temperature sensors market. ... segmented on the basis of types, care setting, ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... today announced that it will launch EMBO Press on ... for The EMBO Journal , EMBO reports , ... provides opportunities for the future development of the journals. ... to encourage transparency in the publication process and help researchers make ...
... is derived from brain tumor stem cells, the source ... unclear. The potential of neural stem cells to transform ... but has not been confirmed. A team led by ... Nanjing Medical University, China found that doxycycline-induced neural stem ...
... Queen,s University Belfast is a lead partner in a ... new ways to treat Cystic Fibrosis. Affecting more ... is one of the most common life-threatening inherited diseases. ... death for patients., The new global programme, known as ...
Cached Biology News:EMBO announces the launch of EMBO Press 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 2Queen's University in €6m bid to find new Cystic Fibrosis treatments 3
... consumable measurement plate for QPatch. ... controlled measurement sites. Each measurement ... flow channel system that enables ... and compound applications necessary for ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... to supply microplates, deepwells, and tips to ... in mind, iLink incorporates multiple functions into ... iLink software is the key to building ... can be copied and installed as turnkey ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
Biology Products: